{"id":"W4416536795","doi":"10.1016/j.ijgc.2025.102795","title":"First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Eisai Canada","keywords":"Pembrolizumab; Lenvatinib; Chemotherapy; Phases of clinical research; Clinical trial","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006942559,0.001044009,0.002887193,0.000510893,0.0007867703,0.00136451,0.0008315235,0.001702985,0.006289404],"category_scores_gemma":[0.005430126,0.0005060756,0.003034485,0.0004483741,0.0004801519,0.001534693,0.0006340028,0.003785778,0.001256279],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001044612,"about_ca_system_score_gemma":0.001124849,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008080177,"about_ca_topic_score_gemma":0.002031802,"domain_scores_codex":[0.9980737,0.0008439203,0.0001596679,0.0003486456,0.000246177,0.0003278211],"domain_scores_gemma":[0.9967722,0.0007159904,0.001141854,0.0003260342,0.0003394305,0.0007042944],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9450064,0.004066695,0.009038044,0.0006348027,0.003784729,0.0001016748,0.00009036682,0.000785867,0.001864268,0.0001162901,0.003433297,0.03107766],"study_design_scores_gemma":[0.4891856,0.3021481,0.1806208,0.0003698097,0.01060918,0.0004037207,0.0001360349,0.002497258,0.003473907,0.0009664597,0.00948604,0.0001030292],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9623383,0.01276117,0.001571728,0.001029866,0.0005926643,0.005250854,0.00986923,0.000197739,0.006388431],"genre_scores_gemma":[0.980132,0.001418929,0.0009767992,0.001140143,0.0002562733,0.004833273,0.00757259,0.00003348772,0.003636612],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006942559,"threshold_uncertainty_score":0.03671616,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0560075135470095,"score_gpt":0.4008194065181933,"score_spread":0.3448118929711838,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}